

John P Bilezikian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3147245/publications.pdf>

Version: 2024-02-01

301
papers

37,106
citations

3874

91
h-index

3844

184
g-index

337
all docs

337
docs citations

337
times ranked

27500
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary hyperparathyroidism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2024, 38, 101247.	2.2	13
2	Vitamin D status in Armenian women: a stratified cross-sectional cluster analysis. European Journal of Clinical Nutrition, 2022, 76, 220-226.	1.3	5
3	Hypocalcemic Crisis: Acute Postoperative and Long-Term Management of Hypocalcemia. , 2022, , 113-124.		0
4	The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 485-501.	2.6	10
5	Hungry bone syndrome following parathyroidectomy for primary hyperparathyroidism in a developed country in the Asia Pacific. A cohort study. Osteoporosis and Sarcopenia, 2022, 8, 11-16.	0.7	3
6	FGF23 levels as a marker of physical performance and falls in community-dwelling very old individuals. Archives of Endocrinology and Metabolism, 2022, , .	0.3	1
7	Skeletal abnormalities in Hypoparathyroidism and in Primary Hyperparathyroidism. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 789-802.	2.6	27
8	Bone Mineral Density: Clinical Relevance and Quantitative Assessment. Journal of Nuclear Medicine, 2021, 62, 446-454.	2.8	25
9	Association between fibroblast growth factor 23 and functional capacity among independent elderly individuals. Einstein (Sao Paulo, Brazil), 2021, 19, eAO5925.	0.3	2
10	The skeletal actions of parathyroid hormone in primary hyperparathyroidism. , 2021, , 1159-1173.		0
11	Clinical Presentation of Hypoparathyroidism. Journal of the Endocrine Society, 2021, 5, bvab003.	0.1	8
12	Primary Hyperparathyroidism: Pathophysiology, Surgical Indications, and Preoperative Workup. , 2021, , 486-493.e2.		1
13	Patients hospitalized with COVID-19 have low levels of 25-hydroxyvitamin D. Endocrine, 2021, 71, 267-269.	1.1	25
14	Clinical phenotypes of primary hyperparathyroidism in hospitalized patients who underwent parathyroidectomy. Endocrine Connections, 2021, 10, 248-255.	0.8	11
15	Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 297-316.	2.6	25
16	Vertebral Fracture Assessment in Postmenopausal Women With Postsurgical Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1303-1311.	1.8	21
17	Post-acute COVID-19 syndrome. Nature Medicine, 2021, 27, 601-615.	15.2	3,051
18	DXA-Based Bone Strain Index: A New Tool to Evaluate Bone Quality in Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2304-2312.	1.8	11

#	ARTICLE	IF	CITATIONS
19	Bone quality in hypoparathyroidism. <i>Minerva Endocrinology</i> , 2021, 46, 325-334.	0.6	1
20	Bone Quality as Measured by Trabecular Bone Score in Normocalcemic Primary Hyperparathyroidism. <i>Endocrine Practice</i> , 2021, 27, 992-997.	1.1	5
21	Rare Causes of Hypercalcemia: 2021 Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3113-3128.	1.8	22
22	Vitamin D: Dosing, levels, form, and route of administration: Does one approach fit all?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 1201-1218.	2.6	74
23	Clinical and translational pharmacology of bisphosphonates. , 2020, , 1671-1687.		1
24	Calcitriol Elevation Is Associated with a Higher Risk of Refractory Hypercalcemia of Malignancy in Solid Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1115-e1123.	1.8	20
25	Pharmacologic mechanisms of therapeutics. , 2020, , 1633-1642.		1
26	Drugs acting on the calcium receptor. , 2020, , 1657-1670.		0
27	Osteoanabolics Versus Antiresorptives: Which First?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 964-965.	1.8	1
28	Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1-84). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3557-e3565.	1.8	16
29	A Simple Formula to Estimate Parathyroid Weight on 4D-CT, Predict Pathologic Weight, and Diagnose Parathyroid Adenoma in Patients with Primary Hyperparathyroidism. <i>American Journal of Neuroradiology</i> , 2020, 41, 1690-1697.	1.2	6
30	Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. <i>Current Medical Research and Opinion</i> , 2020, 36, 1861-1872.	0.9	12
31	Osteitis Fibrosa Cystica. <i>JBMR Plus</i> , 2020, 4, e10403.	1.3	5
32	Controversies in Vitamin D: A Statement From the Third International Conference. <i>JBMR Plus</i> , 2020, 4, e10417.	1.3	118
33	Report on the Audit on Burden of Osteoporosis in Eight Countries of the Eurasian Region: Armenia, Belarus, Georgia, Moldova, Kazakhstan, the Kyrgyz Republic, the Russian Federation, and Uzbekistan. <i>Archives of Osteoporosis</i> , 2020, 15, 175.	1.0	10
34	Hypomagnesuria is Associated With Nephrolithiasis in Patients With Asymptomatic Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2789-e2795.	1.8	12
35	Non-surgical management of primary hyperparathyroidism in the aging population. <i>Maturitas</i> , 2020, 136, 49-53.	1.0	3
36	Changes in Skeletal Microstructure Through Four Continuous Years of rhPTH(1-84) Therapy in Hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1274-1281.	3.1	14

#	ARTICLE	IF	CITATIONS
37	Extrapulmonary manifestations of COVID-19. <i>Nature Medicine</i> , 2020, 26, 1017-1032.	15.2	2,300
38	Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1722-1736.	1.8	103
39	Clinical, Biochemical, and Radiological Profile of Normocalcemic Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2609-e2616.	1.8	37
40	MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19. <i>European Journal of Endocrinology</i> , 2020, 183, R133-R147.	1.9	259
41	Controversies in the treatment of postmenopausal osteoporosis: How long to treat with bisphosphonates?. <i>Archives of Endocrinology and Metabolism</i> , 2020, 64, 331-336.	0.3	5
42	Treatment with Parathyroid Hormone. , 2020, , 25-31.		0
43	PTH and PTHrP Analogs: Treatment of Osteoporosis. <i>Contemporary Endocrinology</i> , 2020, , 349-362.	0.3	0
44	Calcium Citrate Versus Calcium Carbonate in the Management of Chronic Hypoparathyroidism: A Randomized, Double-Blind, Crossover Clinical Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 1251-1259.	3.1	6
45	Therapy of Hypoparathyroidism With rhPTH(1-84): A Prospective, 8-Year Investigation of Efficacy and Safety. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5601-5610.	1.8	53
46	Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. <i>Current Medical Research and Opinion</i> , 2019, 35, 2097-2102.	0.9	25
47	Trabecular bone score: a useful clinical tool for the evaluation of skeletal health in women of short stature. <i>Endocrine</i> , 2019, 66, 398-404.	1.1	8
48	Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5136-5147.	1.8	46
49	Vitamin D supplementation and musculoskeletal health. <i>Lancet Diabetes and Endocrinology</i> , the, 2019, 7, 85-86.	5.5	18
50	Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2748-2756.	1.8	44
51	Three generational phenotypes of sporadic primary hyperparathyroidism: evolution defined by technology. <i>Lancet Diabetes and Endocrinology</i> , the, 2019, 7, 745-747.	5.5	13
52	Diagnostic Performance of 4D CT and Sestamibi SPECT/CT in Localizing Parathyroid Adenomas in Primary Hyperparathyroidism. <i>Radiology</i> , 2019, 291, 469-476.	3.6	101
53	Drugs for the treatment of metabolic bone diseases. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1049-1051.	1.1	7
54	Update on hypoparathyroidism. <i>Current Opinion in Rheumatology</i> , 2019, 31, 381-387.	2.0	12

#	ARTICLE	IF	CITATIONS
55	Osteoanabolic and dual action drugs. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1084-1094.	1.1	45
56	Pharmacology of bisphosphonates. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1052-1062.	1.1	132
57	Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions. <i>Endocrine Reviews</i> , 2019, 40, 1109-1151.	8.9	611
58	Skeletal Microstructure and Estimated Bone Strength Improve Following Parathyroidectomy in Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 196-205.	1.8	45
59	Pre-operative localization of abnormal parathyroid tissue by ^{99m} Tc-sestamibi in primary hyperparathyroidism using four-quadrant site analysis: an evaluation of the predictive value of vitamin D deficiency. <i>Endocrine</i> , 2018, 60, 36-45.	1.1	6
60	Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 722-731.	1.8	59
61	Primary hyperparathyroidism: recent advances. <i>Current Opinion in Rheumatology</i> , 2018, 30, 427-439.	2.0	24
62	Trabecular Bone Score in Obese and Nonobese Subjects With Primary Hyperparathyroidism Before and After Parathyroidectomy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1512-1521.	1.8	27
63	Primary hyperparathyroidism – Hypercalcemic and normocalcemic variants. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2018, 3, 42-50.	0.6	2
64	New and developing pharmacotherapy for osteoporosis in men. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 253-264.	0.9	23
65	Stop the war on DXA!. <i>Annals of the New York Academy of Sciences</i> , 2018, 1433, 12-17.	1.8	10
66	Brown tumors of primary hyperparathyroidism may be a source of extrarenal 1,25-dihydroxyvitamin D production. <i>Endocrine</i> , 2018, 60, 524-527.	1.1	1
67	Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism – translating the pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 252-267.	1.1	35
68	Hyperparathyroidism. <i>Lancet</i> , The, 2018, 391, 168-178.	6.3	371
69	Initiation of dapagliflozin and treatment – emergent fractures. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1070-1074.	2.2	33
70	Primary hyperparathyroidism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2018, 32, 593-607.	2.2	81
71	Management of normocalcemic primary hyperparathyroidism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2018, 32, 837-845.	2.2	55
72	New Directions in Treatment of Hypoparathyroidism. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 901-915.	1.2	10

#	ARTICLE	IF	CITATIONS
73	Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3993-4004.	1.8	197
74	Signs and Symptoms of Hypoparathyroidism. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 759-770.	1.2	32
75	Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2194-2207.	1.1	211
76	The Effects of Long-term Administration of rhPTH(1-84) in Hypoparathyroidism by Bone Histomorphometry. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1931-1939.	3.1	24
77	Comparative Effect of rhPTH(1-84) on Bone Mineral Density and Trabecular Bone Score in Hypoparathyroidism and Postmenopausal Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 2132-2139.	3.1	19
78	ACTIVEExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2949-2957.	1.8	131
79	AHNS Series: Do you know your guidelines? Optimizing outcomes in reoperative parathyroid surgery: Definitive multidisciplinary joint consensus guidelines of the American Head and Neck Society and the British Association of Endocrine and Thyroid Surgeons. <i>Head and Neck</i> , 2018, 40, 1617-1629.	0.9	43
80	Re: A History of Pivotal Advances in Clinical Research Into Bone and Mineral Diseases. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1900-1901.	3.1	1
81	Long-term treatment options for postmenopausal osteoporosis: results of recent clinical studies of Denosumab. <i>Osteoporosis and Bone Diseases</i> , 2018, 21, 17-22.	0.3	14
82	Stress fractures: concepts and therapeutics. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-2720.	1.8	36
83	Parathyroid Hormone Directs Bone Marrow Mesenchymal Cell Fate. <i>Cell Metabolism</i> , 2017, 25, 661-672.	7.2	308
84	Romozosumab for the treatment of osteoporosis. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 255-263.	1.4	78
85	Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis. <i>Mayo Clinic Proceedings</i> , 2017, 92, 200-210.	1.4	109
86	Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study. <i>Endocrine</i> , 2017, 55, 273-282.	1.1	47
87	Novel Therapies for Postmenopausal Osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2017, 46, 207-219.	1.2	25
88	Safety and Efficacy of Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism Randomly Assigned to Receive Fixed 25-1¼g or 50-1¼g Daily Doses. <i>Clinical Therapeutics</i> , 2017, 39, 2096-2102.	1.1	18
89	Hypoparathyroidism. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17055.	18.1	142
90	Osteitis fibrosa cystica—a forgotten radiological feature of primary hyperparathyroidism. <i>Endocrine</i> , 2017, 58, 380-385.	1.1	70

#	ARTICLE	IF	CITATIONS
91	Skeletal changes after restoration of the euparathyroid state in patients with hypoparathyroidism and primary hyperparathyroidism. <i>Endocrine</i> , 2017, 55, 591-598.	1.1	47
92	Sclerostin measurement in human disease: Validity and current limitations. <i>Bone</i> , 2017, 96, 24-28.	1.4	18
93	Vitamin D and primary hyperparathyroidism: more insights into a complex relationship. <i>Endocrine</i> , 2017, 55, 3-5.	1.1	32
94	Primary Hyperparathyroidism; Current Management Guidelines. , 2017, , 331-341.		0
95	Incidence of vertebral fractures in calcium and vitamin D-supplemented postmenopausal Brazilian women with osteopenia or osteoporosis: data from Arzoxifene Generations Trial. <i>Archives of Endocrinology and Metabolism</i> , 2016, 60, 54-59.	0.3	8
96	Effects of Parathyroid Hormone Administration on Bone Strength in Hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1082-1088.	3.1	18
97	Beyond Dxa: Advances in Clinical Applications of New Bone Imaging Technology. <i>Endocrine Practice</i> , 2016, 22, 990-998.	1.1	14
98	Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 681-689.	1.5	31
99	PTH(1-84) Administration in Hypoparathyroidism Transiently Reduces Bone Matrix Mineralization. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 180-189.	3.1	27
100	Primary hyperparathyroidism. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16033.	18.1	180
101	Noninvasive Assessment of Skeletal Microstructure and Estimated Bone Strength in Hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 308-316.	3.1	67
102	Management of Hypoparathyroidism: Present and Future. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2313-2324.	1.8	151
103	Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2742-2750.	1.8	101
104	In vivo precision of digital topological skeletonization based individual trabecula segmentation (ITS) analysis of trabecular microstructure at the distal radius and tibia by HR-pQCT. <i>Pattern Recognition Letters</i> , 2016, 76, 83-89.	2.6	8
105	Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 44-51.	1.8	212
106	Management of Hypoparathyroidism: Summary Statement and Guidelines. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2273-2283.	1.8	303
107	Presentation of Hypoparathyroidism: Etiologies and Clinical Features. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2300-2312.	1.8	246
108	Epidemiology and Diagnosis of Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2284-2299.	1.8	230

#	ARTICLE	IF	CITATIONS
109	Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 157-166.	1.8	356
110	Primary Hyperparathyroidism. <i>F1000Research</i> , 2016, 5, 1.	0.8	117
111	The potential use of antisclerostin therapy in chronic kidney disease “ mineral and bone disorder. <i>Current Opinion in Nephrology and Hypertension</i> , 2015, 24, 1.	1.0	7
112	Spontaneous Remission of Primary Hyperparathyroidism Related to an Autoimmune Disease: A Case Report. <i>AACE Clinical Case Reports</i> , 2015, 1, e255-e259.	0.4	1
113	Hypoglycemia Secondary to Sulfonylurea Ingestion in a Patient with End Stage Renal Disease: Results from a 72-Hour Fast. <i>Case Reports in Endocrinology</i> , 2015, 2015, 1-4.	0.2	2
114	Parathyroid hormone: anabolic and catabolic actions on the skeleton. <i>Current Opinion in Pharmacology</i> , 2015, 22, 41-50.	1.7	355
115	Skeletal Imaging in Primary Hyperparathyroidism. , 2015, , 447-454.		4
116	Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery. <i>European Journal of Endocrinology</i> , 2015, 172, 527-535.	1.9	55
117	PTH(1-84) replacement therapy for the treatment of hypoparathyroidism. <i>Expert Review of Endocrinology and Metabolism</i> , 2015, 10, 5-13.	1.2	22
118	Prevalence of Kidney Stones and Vertebral Fractures in Primary Hyperparathyroidism Using Imaging Technology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1309-1315.	1.8	125
119	How Long to Treat with Denosumab. <i>Current Osteoporosis Reports</i> , 2015, 13, 415-420.	1.5	8
120	Bone Histomorphometry and Bone Quality in Primary Hyperparathyroidism. , 2015, , 429-445.		6
121	Bone Turnover Markers in Primary Hyperparathyroidism. , 2015, , 423-428.		2
122	Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism. , 2015, , 489-497.		3
123	Anabolic and Catabolic Pathways of Parathyroid Hormone on the Skeleton. , 2015, , 233-244.		2
124	Skeletal Manifestations of Hypoparathyroidism. , 2015, , 771-779.		1
125	Asymptomatic Primary Hyperparathyroidism. , 2015, , 317-330.		3
126	Normocalcemic PHPT. , 2015, , 331-339.		7

#	ARTICLE	IF	CITATIONS
127	Parathyroid hormone therapy for hypoparathyroidism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2015, 29, 47-55.	2.2	29
128	Replacement Therapy with PTH(1-84)., 2015, , 333-342.		0
129	Bone disease in primary hyperparathyroidism. Arquivos Brasileiros De Endocrinologia E Metabologia, 2014, 58, 553-561.	1.3	104
130	Bone markers and osteoporosis therapy. Arquivos Brasileiros De Endocrinologia E Metabologia, 2014, 58, 504-513.	1.3	23
131	Hospital care for primary hyperparathyroidism in Italy: a 6-year register-based study. European Journal of Endocrinology, 2014, 171, 481-487.	1.9	12
132	PTH(1-84) Is Associated With Improved Quality of Life in Hypoparathyroidism Through 5 Years of Therapy. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3694-3699.	1.8	104
133	Parathyroid Hormone in the Evaluation of Hypercalcemia. JAMA - Journal of the American Medical Association, 2014, 312, 2680.	3.8	11
134	Parathyroid Hormone 1-84 Alters Circulating Vascular Endothelial Growth Factor Levels in Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2025-E2028.	1.8	5
135	Trabecular Bone Score: A Noninvasive Analytical Method Based Upon the DXA Image. Journal of Bone and Mineral Research, 2014, 29, 518-530.	3.1	617
136	Current Issues in the Presentation of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Fourth International Workshop. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3580-3594.	1.8	318
137	Update on romosozumab: a humanized monoclonal antibody to sclerostin. Expert Opinion on Biological Therapy, 2014, 14, 697-707.	1.4	30
138	Bone Density Testing: Science, the Media, and Patient Care. Current Osteoporosis Reports, 2014, 12, 227-229.	1.5	7
139	Utility of the trabecular bone score (TBS) in secondary osteoporosis. Endocrine, 2014, 47, 435-448.	1.1	120
140	Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Fourth International Workshop. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3561-3569.	1.8	1,277
141	Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone, 2014, 59, 173-179.	1.4	135
142	Trabecular bone score: perspectives of an imaging technology coming of age. Arquivos Brasileiros De Endocrinologia E Metabologia, 2014, 58, 493-503.	1.3	51
143	New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide. Bone Research, 2014, 2, 14043.	5.4	8
144	Osteoporosis in Men. , 2014, , 323-333.		1

#	ARTICLE	IF	CITATIONS
145	Combination therapy with risedronate and teriparatide in male osteoporosis. <i>Endocrine</i> , 2013, 44, 237-246.	1.1	63
146	Asymptomatic Primary Hyperparathyroidism. <i>Journal of Clinical Densitometry</i> , 2013, 16, 14-21.	0.5	83
147	New Approaches to Osteoporosis Therapeutics. , 2013, , 1963-1985.		0
148	The Effect of PTH(1-84) on Quality of Life in Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2356-2361.	1.8	169
149	Idiopathic Osteoporosis in Men. <i>Current Osteoporosis Reports</i> , 2013, 11, 286-298.	1.5	21
150	Recovery of Parathyroid Hormone Secretion and Function in Postoperative Hypoparathyroidism: A Case Series. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4285-4290.	1.8	19
151	New insights into the effects of primary hyperparathyroidism on the cortical and trabecular compartments of bone. <i>Bone</i> , 2013, 55, 57-63.	1.4	76
152	Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 275-283.	5.5	244
153	Bone Turnover Markers in Primary Hyperparathyroidism. <i>Journal of Clinical Densitometry</i> , 2013, 16, 22-27.	0.5	34
154	Normocalcemic Primary Hyperparathyroidism. <i>Journal of Clinical Densitometry</i> , 2013, 16, 33-39.	0.5	145
155	Trabecular Bone Score Is Associated With Volumetric Bone Density and Microarchitecture as Assessed by Central QCT and HRpQCT in Chinese American and White Women. <i>Journal of Clinical Densitometry</i> , 2013, 16, 554-561.	0.5	73
156	Osteoporosis Update From the 2012 Santa Fe Bone Symposium. <i>Journal of Clinical Densitometry</i> , 2013, 16, 584-600.	0.5	14
157	Therapy of Hypoparathyroidism with PTH(1-84): A Prospective Four-Year Investigation of Efficacy and Safety. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 137-144.	1.8	148
158	Rosiglitazone Decreases Bone Mineral Density and Increases Bone Turnover in Postmenopausal Women With Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1519-1528.	1.8	92
159	Circulating Sclerostin Levels and Markers of Bone Turnover in Chinese-American and White Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4736-4743.	1.8	24
160	Does calcium intake influence the development of primary hyperparathyroidism?. <i>IBMS BoneKEy</i> , 2013, 10, .	0.1	2
161	Osteoporosis. <i>Clinical Obstetrics and Gynecology</i> , 2013, 56, 730-738.	0.6	5
162	The Skeletal Actions of Parathyroid Hormone in Primary Hyperparathyroidism and in Osteoporosis. , 2013, , 1249-1265.		0

#	ARTICLE	IF	CITATIONS
163	Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1029-1040.	3.1	174
164	Normocalcemic Hyperparathyroidism and Hypoparathyroidism in Two Community-Based Nonreferral Populations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2734-2741.	1.8	116
165	Primary Hyperparathyroidism: A Tale of Two Cities Revisited – New York and Shanghai. <i>Bone Research</i> , 2013, 1, 162-169.	5.4	45
166	Diagnosis and management of primary hyperparathyroidism: a scientific statement from the Department of Bone Metabolism, the Brazilian Society for Endocrinology and Metabolism. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2013, 57, 406-424.	1.3	54
167	Primary Hyperparathyroidism. <i>Endocrine Practice</i> , 2012, 18, 781-790.	1.1	35
168	Effect of Renal Function on Skeletal Health in Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1501-1507.	1.8	36
169	Combination Anabolic and Antiresorptive Therapy for Osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2012, 41, 643-654.	1.2	22
170	Safety of osteoanabolic therapy: A decade of experience. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 2419-2428.	3.1	125
171	Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. <i>Journal of Drug Assessment</i> , 2012, 1, 11-19.	1.1	5
172	Patient-specific bone modelling and remodelling simulation of hypoparathyroidism based on human iliac crest biopsies. <i>Journal of Biomechanics</i> , 2012, 45, 2411-2416.	0.9	27
173	Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1802-1822.	1.8	480
174	More bone density testing is needed, not less. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 739-742.	3.1	37
175	Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2990-3011.	1.8	1,127
176	Sclerostin: Therapeutic Horizons Based Upon Its Actions. <i>Current Osteoporosis Reports</i> , 2012, 10, 64-72.	1.5	62
177	Mini-review: new therapeutic options in hypoparathyroidism. <i>Endocrine</i> , 2012, 41, 410-414.	1.1	32
178	Combination antiresorptive and osteoanabolic therapy for osteoporosis: We are not there yet. <i>Current Medical Research and Opinion</i> , 2011, 27, 1705-1707.	0.9	18
179	Osteoporosis Update From the 2010 Santa Fe Bone Symposium. <i>Journal of Clinical Densitometry</i> , 2011, 14, 1-21.	0.5	22
180	Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. <i>Nature Reviews Rheumatology</i> , 2011, 7, 447-456.	3.5	233

#	ARTICLE	IF	CITATIONS
181	New Approaches to the Treatment of Osteoporosis. Annual Review of Medicine, 2011, 62, 307-322.	5.0	35
182	Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism. Bone, 2011, 48, 557-561.	1.4	59
183	Therapy of Osteoporosis in Men with Teriparatide. Journal of Osteoporosis, 2011, 2011, 1-7.	0.1	18
184	Lawrence G. Raisz November 13, 1925â€“August 25, 2010. Journal of Bone and Mineral Research, 2011, 26, 903-911.	3.1	1
185	Better skeletal microstructure confers greater mechanical advantages in Chinese-American women versus white women. Journal of Bone and Mineral Research, 2011, 26, 1783-1792.	3.1	80
186	PTH(1â€“84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. Journal of Bone and Mineral Research, 2011, 26, 2727-2736.	3.1	122
187	Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. Journal of Bone and Mineral Research, 2011, 26, 2317-2337.	3.1	485
188	Circulating Sclerostin in Disorders of Parathyroid Gland Function. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3804-3810.	1.8	68
189	High-resolution peripheral quantitative computed tomography can assess microstructural and mechanical properties of human distal tibial bone. Journal of Bone and Mineral Research, 2010, 25, 746-756.	3.1	160
190	Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement. Arquivos Brasileiros De Endocrinologia E Metabologia, 2010, 54, 220-226.	1.3	47
191	Teriparatide: Variations on the theme of a 2-year therapeutic course. IBMS BoneKEy, 2010, 7, 84-87.	0.1	6
192	2009 Santa Fe Bone Symposium. Journal of Clinical Densitometry, 2010, 13, 1-9.	0.5	17
193	Three dimensional cancellous bone structure in hypoparathyroidism. Bone, 2010, 46, 190-195.	1.4	84
194	Normocalcemic primary hyperparathyroidism. Arquivos Brasileiros De Endocrinologia E Metabologia, 2010, 54, 106-109.	1.3	88
195	Primary Hyperparathyroidism in Men. , 2010, , 465-478.		1
196	Asymptomatic Primary Hyperparathyroidism: a Commentary on the Revised Guidelines. Endocrine Practice, 2009, 15, 494-498.	1.1	13
197	Alendronate Therapy in Men With Primary Hyperparathyroidism. Endocrine Practice, 2009, 15, 705-713.	1.1	51
198	Morphometric Vertebral Fractures in Postmenopausal Women with Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2306-2312.	1.8	170

#	ARTICLE	IF	CITATIONS
199	The Diagnosis and Management of Asymptomatic Primary Hyperparathyroidism Revisited. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 333-334.	1.8	83
200	Cinacalcet Reduces Serum Calcium Concentrations in Patients with Intractable Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2766-2772.	1.8	134
201	Efficacy of Bisphosphonates in Reducing Fracture Risk in Postmenopausal Osteoporosis. <i>American Journal of Medicine</i> , 2009, 122, S14-S21.	0.6	140
202	The Official Positions of the International Society for Clinical Densitometry: Perceptions and Commentary. <i>Journal of Clinical Densitometry</i> , 2009, 12, 267-271.	0.5	32
203	Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International Workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 335-339.	1.8	793
204	Combination anabolic and antiresorptive therapy for osteoporosis: Opening the anabolic window. <i>Current Osteoporosis Reports</i> , 2008, 6, 24-30.	1.5	103
205	The cell biology of parathyroid hormone in osteoblasts. <i>Current Osteoporosis Reports</i> , 2008, 6, 72-76.	1.5	83
206	Parathyroid hormone and the cardiovascular system. <i>Current Osteoporosis Reports</i> , 2008, 6, 77-83.	1.5	102
207	Osteoporosis in men: Pathophysiology and treatment. <i>Current Sexual Health Reports</i> , 2008, 5, 83-89.	0.4	0
208	Dynamic and Structural Properties of the Skeleton in Hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 2018-2024.	3.1	176
209	Parathyroid Carcinoma. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1869-1880.	3.1	243
210	Official Positions of the International Society for Clinical Densitometry and Executive Summary of the 2007 ISCD Position Development Conference. <i>Journal of Clinical Densitometry</i> , 2008, 11, 75-91.	0.5	379
211	Racial differences in bone density and fracture risk in the United States. <i>International Journal of Rheumatic Diseases</i> , 2008, 11, 341-346.	0.9	10
212	Bone Quality determined by Fourier Transform Infrared Imaging Analysis in Mild Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3484-3489.	1.8	23
213	Differentiation and Proliferation of Periosteal Osteoblast Progenitors Are Differentially Regulated by Estrogens and Intermittent Parathyroid Hormone Administration. <i>Endocrinology</i> , 2008, 149, 5713-5723.	1.4	71
214	The Natural History of Primary Hyperparathyroidism with or without Parathyroid Surgery after 15 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3462-3470.	1.8	505
215	Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3785-3793.	1.8	205
216	Mechanisms of Anabolic Therapies for Osteoporosis. <i>New England Journal of Medicine</i> , 2007, 357, 905-916.	13.9	573

#	ARTICLE	IF	CITATIONS
217	Occurrence of Hypercalciuria in Patients with Osteoporosis Treated with Teriparatide. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3535-3541.	1.8	55
218	Surgery or Surveillance for Mild Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3114-3121.	1.8	347
219	Elevations in Serum and Urinary Calcium with Parathyroid Hormone (1-84) with and without Alendronate for Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 942-947.	1.8	26
220	Anabolic Therapy for Osteoporosis. Women's Health, 2007, 3, 243-253.	0.7	8
221	An N-Terminal Molecular Form of Parathyroid Hormone (PTH) Distinct from hPTH(1-84) Is Overproduced in Parathyroid Carcinoma. Clinical Chemistry, 2007, 53, 1470-1476.	1.5	81
222	Glucocorticoid-Induced osteoporosis: clinical and therapeutic aspects. Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 1404-1412.	1.3	30
223	Osteoporosis in Men. Endocrinology and Metabolism Clinics of North America, 2007, 36, 399-419.	1.2	86
224	New Observations on Bone Quality in Mild Primary Hyperparathyroidism as Determined by Quantitative Backscattered Electron Imaging. Journal of Bone and Mineral Research, 2007, 22, 717-723.	3.1	71
225	Osteoporosis in Men: Pathophysiology and treatment. Current Osteoporosis Reports, 2007, 5, 22-28.	1.5	5
226	The use of parathyroid hormone in the treatment of osteoporosis. Reviews in Endocrine and Metabolic Disorders, 2007, 7, 113-121.	2.6	114
227	Osteoporosis in men: Pathophysiology and treatment. Current Rheumatology Reports, 2007, 9, 71-77.	2.1	9
228	Glucocorticoid-induced osteoporosis: an update. Trends in Endocrinology and Metabolism, 2006, 17, 144-149.	3.1	311
229	Asymptomatic primary hyperparathyroidism. Arquivos Brasileiros De Endocrinologia E Metabologia, 2006, 50, 647-656.	1.3	21
230	Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis. Current Osteoporosis Reports, 2006, 4, 5-13.	1.5	22
231	Estrogen in men: effects on bone accrual, maintenance and prevention of bone loss. Expert Review of Endocrinology and Metabolism, 2006, 1, 281-295.	1.2	6
232	Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. European Journal of Endocrinology, 2005, 152, 199-205.	1.9	66
233	Cinacalcet Hydrochloride Maintains Long-Term Normocalcemia in Patients with Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 135-141.	1.8	425
234	Arterial Stiffness in Mild Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3326-3330.	1.8	132

#	ARTICLE	IF	CITATIONS
235	Parathyroid Hormone as an Anabolic Skeletal Therapy. <i>Drugs</i> , 2005, 65, 2481-2498.	4.9	69
236	One Year of Alendronate after One Year of Parathyroid Hormone (1 μ g) for Osteoporosis. <i>New England Journal of Medicine</i> , 2005, 353, 555-565.	13.9	568
237	Anabolic therapy for osteoporosis. <i>International Journal of Fertility and Women's Medicine</i> , 2005, 50, 53-60.	0.4	5
238	Alendronate in Primary Hyperparathyroidism: A Double-Blind, Randomized, Placebo-Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3319-3325.	1.8	262
239	Aromatase Activity and Bone Homeostasis in Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5898-5907.	1.8	164
240	The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. <i>Osteoporosis International</i> , 2004, 15, 992-997.	1.3	161
241	Asymptomatic Primary Hyperparathyroidism. <i>New England Journal of Medicine</i> , 2004, 350, 1746-1751.	13.9	328
242	Asymptomatic primary hyperparathyroidism: a medical perspective. <i>Surgical Clinics of North America</i> , 2004, 84, 787-801.	0.5	30
243	Serum vitamin A concentration and the risk of hip fracture among women 50 to 74 years old in the United States: A prospective analysis of the NHANES I follow-up study. <i>American Journal of Medicine</i> , 2004, 117, 169-174.	0.6	62
244	Bone strength in primary hyperparathyroidism. <i>Osteoporosis International</i> , 2003, 14, 113-117.	1.3	37
245	New anabolic therapies in osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2003, 32, 285-307.	1.2	60
246	The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis. <i>New England Journal of Medicine</i> , 2003, 349, 1207-1215.	13.9	1,133
247	The anabolic effects of parathyroid hormone therapy. <i>Clinics in Geriatric Medicine</i> , 2003, 19, 415-432.	1.0	93
248	The Calcimimetic Cinacalcet Normalizes Serum Calcium in Subjects with Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5644-5649.	1.8	235
249	Incipient Primary Hyperparathyroidism: A Forme Fruste of an Old Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5348-5352.	1.8	186
250	Effects of Intermittent Parathyroid Hormone Administration on Bone Mineralization Density in Iliac Crest Biopsies from Patients with Osteoporosis: A Paired Study before and after Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 1150-1156.	1.8	228
251	Clinical Utility of an Immunoradiometric Assay for Parathyroid Hormone (1 μ g) in Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4725-4730.	1.8	94
252	When should a gynecologist refer a patient for specialty care in osteoporosis?. <i>International Journal of Fertility and Women's Medicine</i> , 2003, 48, 132-6; discussion 137-8.	0.4	0

#	ARTICLE	IF	CITATIONS
253	The Role of Parathyroid Hormone in the Pathogenesis of Glucocorticoid-Induced Osteoporosis: A Re-Examination of the Evidence. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 4033-4041.	1.8	173
254	Summary Statement from a Workshop on Asymptomatic Primary Hyperparathyroidism: A Perspective for the 21st Century. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 5353-5361.	1.8	577
255	Sex Steroids, Mice, and Men: When Androgens and Estrogens Get Very Close to Each Other. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 563-566.	3.1	51
256	Primary Hyperparathyroidism: Epidemiology and Clinical Consequences. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2002, 1, 25-34.	1.3	3
257	Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. <i>Journal of Bone and Mineral Research</i> , 2002, 17 Suppl 2, N2-11.	3.1	37
258	Asymptomatic primary hyperparathyroidism: new issues and new questions--bridging the past with the future. <i>Journal of Bone and Mineral Research</i> , 2002, 17 Suppl 2, N57-67.	3.1	15
259	Effects of Daily Treatment with Parathyroid Hormone on Bone Microarchitecture and Turnover in Patients with Osteoporosis: A Paired Biopsy Study*. <i>Journal of Bone and Mineral Research</i> , 2001, 16, 1846-1853.	3.1	580
260	Anabolic Therapy for Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 957-964.	1.8	187
261	Tc99m-Sestamibi Uptake in Osteitis Fibrosa Cystica Simulating Metastatic Bone Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5138-5141.	1.8	26
262	Clinical spectrum of primary hyperparathyroidism. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2000, 1, 237-245.	2.6	60
263	Parathyroid Hormone as a Therapy for Idiopathic Osteoporosis in Men: Effects on Bone Mineral Density and Bone Markers1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3069-3076.	1.8	331
264	Osteoporosis in Men*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 3431-3434.	1.8	189
265	A 10-Year Prospective Study of Primary Hyperparathyroidism with or without Parathyroid Surgery. <i>New England Journal of Medicine</i> , 1999, 341, 1249-1255.	13.9	822
266	The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. <i>American Journal of Medicine</i> , 1999, 107, 561-567.	0.6	231
267	Estrogens and Postmenopausal Osteoporosis: Was Albright Right After All?. <i>Journal of Bone and Mineral Research</i> , 1998, 13, 774-776.	3.1	30
268	Intracellular Ca ²⁺ Homeostasis in Trypomastigotes of <i>Trypanosoma cruzi</i> . <i>Journal of Eukaryotic Microbiology</i> , 1998, 45, 80-86.	0.8	7
269	Increased Bone Mass as a Result of Estrogen Therapy in a Man with Aromatase Deficiency. <i>New England Journal of Medicine</i> , 1998, 339, 599-603.	13.9	585
270	Treatment of Hypercalcemia Secondary to Parathyroid Carcinoma with a Novel Calcimimetic Agent. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 1083-1088.	1.8	160

#	ARTICLE	IF	CITATIONS
271	Marked Improvement in Bone Mass after Parathyroidectomy in Osteitis Fibrosa Cystica ¹ . Journal of Clinical Endocrinology and Metabolism, 1998, 83, 732-735.	1.8	60
272	Normal Growth Hormone Secretary Reserve in Men with Idiopathic Osteoporosis and Reduced Circulating Levels of Insulin-Like Growth Factor-1I. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2576-2579.	1.8	58
273	Insulin-Like Growth Factor-I in Men with Idiopathic Osteoporosis ¹ . Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2799-2805.	1.8	167
274	Hypoparathyroidism. Current Opinion in Endocrinology, Diabetes and Obesity, 1997, 4, 427-432.	0.6	9
275	Optimal Dietary Calcium Intake in Primary Hyperparathyroidism. American Journal of Medicine, 1997, 102, 543-550.	0.6	59
276	Primary Hyperparathyroidism: Still Evolving?. Journal of Bone and Mineral Research, 1997, 12, 856-862.	3.1	73
277	Positive Chronotropic Actions of Parathyroid Hormone and Parathyroid Hormone-Related Peptide Are Associated With Increases in the Current, I_{CaT} , and the Slope of the Pacemaker Potential. Circulation, 1997, 96, 3704-3709.	1.6	48
278	Release of guanosine triphosphate binding protein \hat{A} subunits from mouse myocardial membranes: Basic properties and their alterations in acute murine Chagas disease. Cardiovascular Research, 1995, 29, 350-358.	1.8	1
279	Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. Journal of Bone and Mineral Research, 1995, 10, 1393-1399.	3.1	127
280	Hypocalcemic Emergencies. Endocrinology and Metabolism Clinics of North America, 1993, 22, 363-375.	1.2	87
281	Management of Acute Hypercalcemia. New England Journal of Medicine, 1992, 326, 1196-1203.	13.9	267
282	Maintenance of cancellous bone connectivity in primary hyperparathyroidism: Trabecular strut analysis. Journal of Bone and Mineral Research, 1992, 7, 913-920.	3.1	130
283	Effects of guanine nucleotides and parathyroid hormone on inositol 1,4,5-trisphosphate metabolism in canine renal cortical tubular cell membranes. Journal of Bone and Mineral Research, 1991, 6, 599-607.	3.1	0
284	Parathyroid hormone stimulates formation of inositol phosphates in a membrane preparation of canine renal cortical tubular cells. Journal of Bone and Mineral Research, 1990, 5, 299-306.	3.1	20
285	The Histomorphometry of Bone in Primary Hyperparathyroidism: Preservation of Cancellous Bone Structure*. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 930-938.	1.8	318
286	Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. American Journal of Medicine, 1989, 87, 553-557.	0.6	118
287	Skeletal disease in primary hyperparathyroidism. Journal of Bone and Mineral Research, 1989, 4, 283-291.	3.1	553
288	Stimulation of inositol phosphate formation in ros 17/2.8 cell membranes by guanine nucleotide, calcium, and parathyroid hormone. Journal of Bone and Mineral Research, 1989, 4, 413-420.	3.1	43

#	ARTICLE	IF	CITATIONS
289	Infection of L6E9 myoblasts with <i>Trypanosoma cruzi</i> alters adenylate cyclase activity and guanine nucleotide binding proteins. <i>Journal of Cellular Physiology</i> , 1987, 133, 64-71.	2.0	11
290	Modifications of the adenylate cyclase complex during differentiation of cultured myoblasts. <i>Journal of Cellular Physiology</i> , 1986, 127, 28-38.	2.0	16
291	Enhancement of parathyroid hormone-responsive renal cortical adenylate cyclase activity by a cytosol protein activator from rat reticulocytes. <i>Journal of Bone and Mineral Research</i> , 1986, 1, 41-50.	3.1	1
292	The effect of oral phosphate administration on major indices of skeletal metabolism in normal subjects. <i>Journal of Bone and Mineral Research</i> , 1986, 1, 383-388.	3.1	75
293	The Influence of Hypermagnesemia on Serum Calcium and Parathyroid Hormone Levels in Human Subjects. <i>New England Journal of Medicine</i> , 1984, 310, 1221-1225.	13.9	262
294	Endothelial cells contain beta adrenoceptors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1984, 325, 310-313.	1.4	64
295	Reticulocyte Cytosol Activator Protein: Its Actions Upon the Beta Adrenergic Receptor and the N-Proteins of Adenylate Cyclase. <i>Journal of Receptors and Signal Transduction</i> , 1984, 4, 475-486.	1.2	1
296	Total and free propranolol levels in sensitive and resistant patients. <i>Clinical Pharmacology and Therapeutics</i> , 1983, 33, 163-171.	2.3	9
297	Case Report Vitamin A Toxicity and Hypercalcemia. <i>American Journal of the Medical Sciences</i> , 1982, 283, 161-164.	0.4	52
298	A radioreceptor assay for propranolol and 4-hydroxypropranolol. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 28, 32-39.	2.3	13
299	A radioreceptor assay for propranolol. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 26, 173-180.	2.3	22
300	Chapter 66. Primary Hyperparathyroidism. , 0, , 301-306.		2
301	Bone Densitometry: The Best Way to Detect Osteoporosis and to Monitor Therapy. , 0, .		55